[HTML][HTML] Human endogenous retrovirus K in cancer: a potential biomarker and immunotherapeutic target
G Curty, JL Marston, M de Mulder Rougvie, FE Leal… - Viruses, 2020 - mdpi.com
In diseases where epigenetic mechanisms are changed, such as cancer, many genes show
altered gene expression and inhibited genes become activated. Human endogenous
retrovirus type K (HERV-K) expression is usually inhibited in normal cells from healthy
adults. In tumor cells, however, HERV-K mRNA expression has been frequently documented
to increase. Importantly, HERV-K-derived proteins can act as tumor-specific antigens, a
class of neoantigens, and induce immune responses in different types of cancer. In this …
altered gene expression and inhibited genes become activated. Human endogenous
retrovirus type K (HERV-K) expression is usually inhibited in normal cells from healthy
adults. In tumor cells, however, HERV-K mRNA expression has been frequently documented
to increase. Importantly, HERV-K-derived proteins can act as tumor-specific antigens, a
class of neoantigens, and induce immune responses in different types of cancer. In this …
In diseases where epigenetic mechanisms are changed, such as cancer, many genes show altered gene expression and inhibited genes become activated. Human endogenous retrovirus type K (HERV-K) expression is usually inhibited in normal cells from healthy adults. In tumor cells, however, HERV-K mRNA expression has been frequently documented to increase. Importantly, HERV-K-derived proteins can act as tumor-specific antigens, a class of neoantigens, and induce immune responses in different types of cancer. In this review, we describe the function of the HERV-K HML-2 subtype in carcinogenesis as biomarkers, and their potential as targets for cancer immunotherapy.
MDPI